Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves MDRNA's Non-RNAi Generic Osteoporosis Drug

Premium

MDRNA said this week that the US Food and Drug Administration has approved the company's abbreviated new drug application for a generic version of calcitonin-salmon nasal spray for osteoporosis.

The spray is a legacy product from Nastech Pharmaceutical, an intranasal drug-delivery firm that reorganized into RNAi therapeutics shop MDRNA this time last year (see RNAi News, 6/12/2008).

Under a deal signed in March, Par Pharmaceutical acquired the rights to the spray in exchange for an upfront fee and profit sharing for five years (see RNAi News, 4/2/2009).

"Revenue generated from the sale of calcitonin-salmon by Par will provide us with working capital to help advance our RNAi programs," MDRNA President and CEO Michael French said in a statement this week.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.